Physician profile
Ray C Whetstone
NPI 1124142047
$2,846.70
in general payments reported to CMS, 2019-2025
13 companies · $645 in 2025
The $645 reported for 2025 was more than what 83% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $154 · 2020: $255 · 2021: $558 · 2022: $350 · 2023: $540 · 2024: $345 · 2025: $645.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,530.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,530.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,841.03 | 2019-2025 | Total30, Precision7, Precision 1 |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $179.36 | 2019-2021 | |
| Bausch & Lomb Americas INC. | $172.11 | 2023-2025 | Miebo, Infuse, Btod |
| Regeneron Healthcare Solutions, INC. | $168.89 | 2024-2025 | Eylea Hd, Eylea |
| Sight Sciences, INC. | $148.55 | 2021-2025 | Tearcare System |
| Astellas Pharma US INC | $86.35 | 2024-2025 | Izervay |
| Optos, INC. | $81.76 | 2019-2021 | |
| Abbvie INC. | $55.71 | 2022-2023 | Ozurdex |
| Kala Pharmaceuticals, INC. | $29.55 | 2019-2020 | |
| Genzyme Corporation | $23.33 | 2021 | |
| Ani Pharmaceuticals, INC. | $20.57 | 2025 | Iluvien |
| Aerie Pharmaceuticals, INC. | $19.95 | 2021 | |
| Alimera Sciences, INC. | $19.54 | 2023 | Iluvien |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ray Whetstone listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.